



Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy



Giuseppe Liberatore^{a,*}, Claudia Giannotta^a, Blesson Punnen Sajeev^a, Emanuela Morengi^b, Fabrizia Terenghi^a, Francesca Gallia^a, Pietro Emiliano Doneddu^a, Fiore Manganelli^c, Dario Cocito^d, Massimiliano Filosto^e, Giovanni Antonini^f, Giuseppe Cosentino^g, Girolama Alessandra Marfia^h, Angelo Maurizio Clericiⁱ, Giuseppe Lauria^{j,k}, Tiziana Rosso^l, Guido Cavaletti^m, Eduardo Nobile-Orazio^{a,n}

^a Neuromuscular and Neuroimmunology Service, Humanitas Clinical and Research Institute, Rozzano, Milan, Italy

^b Biostatistics Unit, Humanitas Clinical and Research Institute, Rozzano, Milan, Italy

^c Department of Neuroscience, Reproductive Sciences and Odontostomatology, University of Naples 'Federico II', Naples, Italy

^d Presidio Sanitario Major, Istituti Clinici Scientifici Maugeri, Turin, Italy

^e Center for Neuromuscular Diseases and Neuropathies, Unit of Neurology, ASST 'Spedali Civili', University of Brescia, Brescia, Italy

^f Unit of Neuromuscular Diseases, Department of Neurology Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, 'Sapienza' University of Rome, Sant'Andrea Hospital, Rome, Italy

^g Department of Experimental BioMedicine and Clinical Neurosciences (BioNeC), University of Palermo, Palermo, Italy

^h Dysimmune Neuropathies Unit, Department of Systems Medicine, Tor Vergata University of Rome, Rome, Italy

ⁱ Neurology Unit, Circolo & Macchi Foundation Hospital, Insubria University, DBSV, Varese, Italy

^j Unit of Neurology, IRCCS Foundation 'Carlo Besta' Neurological Institute, Milan, Italy

^k Department of Biomedical and Clinical Sciences 'Luigi Sacco', University of Milan, Milan, Italy

^l ULSS2 Marca Trevigiana, UOC Neurologia-Castelfranco Veneto, Treviso, Italy

^m School of Medicine and Surgery and Experimental Neurology Unit, University of Milano-Bicocca, Monza, Italy

ⁿ Department of Medical Biotechnology and Translational Medicine, Milan University, Milan, Italy

ARTICLE INFO

Keywords:

Anti-MAG polyneuropathy, chronic inflammatory demyelinating polyradiculoneuropathy, ELISA, Sensitivity, Specificity

ABSTRACT

For the diagnosis of anti-MAG polyneuropathy the commercial ELISA manufacturer currently recommends a cut-off of 1000 Bühlmann Titer Units (BTU). We analyzed sera from 80 anti-MAG neuropathy patients and 383 controls (with other neuropathies or healthy controls) to assess the ELISA sensitivity and specificity at different thresholds. A better combination of sensitivity/specificity was found at a threshold > 1500 BTU than at > 1000 BTU. The best value of specificity was obtained at threshold > 7000 BTU. There was a diagnostic grey area between 1500 and 7000 BTU in which the clinical phenotypes as well as electrophysiological studies need to be carefully assessed particularly to differentiate CIDP and anti-MAG neuropathy.

1. Introduction

Anti-MAG neuropathy is a disorder of the peripheral nervous system linked to the presence of antibodies against the myelin-associated glycoprotein (MAG). It was originally reported in a patient with neuropathy and IgM monoclonal gammopathy of undetermined significance (MGUS) whose IgM bound to an antigen in myelin later identified as MAG (Latov et al., 1980). Anti-MAG neuropathy typically present as a

distal acquired demyelinating symmetric (DADS) predominantly sensory neuropathy with ataxia and moderate motor impairment (Nobile-Orazio et al., 1994; Chaudhry et al., 2017; Dalakas, 2018). It is a subtype of paraproteinemic neuropathy, a collective term used to refer to neuropathies associated with a serum monoclonal gammopathy (Gosselin et al., 1991; Nobile-Orazio, 2013).

Nowadays, the anti-MAG IgM ELISA from Bühlmann is the most frequently used commercial assay to detect these antibodies and was

Abbreviations: BTU, Bühlmann Titer Units; MAG, Myelin-Associated Glycoprotein; CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy; DADS, Distal Acquired Demyelinating Symmetric Neuropathy; POEMS, Polineuropathy Organomegaly Endocrinopathy M-protein Skin; ALS, Amyotrophic Lateral Sclerosis; PPV, Positive Predictive Value; NPV, Negative Predictive Value

* Corresponding author at: Neuromuscular and Neuroimmunology Service, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, Milan 20089, Italy.

E-mail address: giuseppe.liberatore@humanitas.it (G. Liberatore).

<https://doi.org/10.1016/j.jneuroim.2020.577288>

Received 7 April 2020; Received in revised form 10 May 2020; Accepted 5 June 2020

0165-5728/© 2020 Elsevier B.V. All rights reserved.

reported to be more sensitive even if less specific than previously ubiquitously used home-made or commercial Western Blot (Kuijf et al., 2009). The result of this test is expressed in Bühlmann Titer Units (BTU), with a recommended cut-off level for positivity of 1000 BTU. However, the cut-off for positivity for this assay is debated with some studies reporting that some patients with BTU titers > 1000 BTU may have an alternative diagnosis to anti-MAG neuropathy (Caudie et al., 2006; Kuijf et al., 2009).

The aim of our work was to define the ideal cut-off value for positivity from the analysis of our series of patients with anti-MAG neuropathy, other neuropathies and healthy subjects; and to correlate the results with those obtained by our home-made Western blot assay.

2. Patients and methods

This was a retrospective, observational case-control diagnostic accuracy study. We analyzed a total of 463 sera, including 80 patients with anti-MAG neuropathy, 222 with CIDP diagnosed according to the EFNS/PNS criteria (van den Bergh et al., 2010), 38 with POEMS syndrome (Dispenzieri et al., 2018), 30 with ALS (Brooks et al., 2000), 73 with other neuropathies (including diabetic, vasculitic, paraneoplastic, amyloidosis, motor multifocal neuropathy, hereditary, sensitive neuropathy of undefined origin), 20 healthy controls. Patients with a diagnosis of anti-MAG neuropathy had a chronic progressive demyelinating neuropathy associated with IgM monoclonal gammopathy (Nobile-Orazio et al., 1994) fulfilling the EFNS/PNS electrodiagnostic criteria for demyelination (Hadden et al., 2006) and increased titers of anti-MAG IgM antibodies by Western blot (Nobile-Orazio et al., 2008). In all patients blood was taken at the time of our first neurological assessment and the same sample of serum was used for ELISA and Western blot.

Anti-MAG reactivity was determined by ELISA using a commercial available system (Anti-MAG ELISA; Bühlmann Laboratories, Switzerland) according to manufacturer's instructions. Results are expressed in arbitrary units (Bühlmann Titer Units, BTU) and the cut-off of positivity (ELISA's manufacturer established) is 1000 BTU. All the sera were tested in duplicated. In all the measurements, sera from two positive patients were included to ascertain the reproducibility of the data and the variation of the results that was always within a 10% of variation. Patients with moderately increased levels (1000 to 10,000 BTU) were also repeated at least once to confirm the data.

All patients with anti-MAG neuropathy and 206 patients of other subgroups (32 with CIDP, 11 with ALS, 9 with POEMS, 54 other neuropathies, 20 healthy controls) were tested for anti-MAG IgM antibodies by Western blot after electrophoresis (normal value up to 1:3200) according to our previously described procedures (Nobile-Orazio et al., 1983). Antibody titers were determined by disappearance of the visible band of band of MAG by Western blot. Illustrative examples of the results of Western blot were previously reported (Nobile-Orazio et al., 2008; Nobile-Orazio, 2013).

We calculate sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of ELISA method using different cut-off values: > 1000 BTU, > 1500 BTU, > 3000 BTU, > 6000 BTU, > 7000 BTU, > 10,000 BTU. Correlation between variables was explored with Pearson correlation index. All analyses were performed with Stata15 software (StataCorp LLC, USA).

3. Results

Table 1 summarize results of sensitivity and specificity of ELISA method at different cut-off values. With a cut-off of > 1000 BTU, twenty-three patients would have been false positive: twenty CIDP patients, two POEMS patients and one 'other neuropathy' patient (sensitivity 100%, specificity 93.99%). Consequently, we chose a value > 1500 BTU as the lowest cut-off, based on a previous study which established that the recommended cut-off of 1000 BTU was too

Table 1

values of sensitivity, specificity, PPV, NPV, accuracy at different threshold of BTU (anti-MAG patients vs entire cohort of control sample). The best value of Sensitivity was found at > 1500 BTU, the best value of Specificity and Accuracy at > 7000 BTU.

Threshold	Sensitivity	Specificity	PPV	NPV	Accuracy
> 1000 BTU	100%	93.99%	77.67%	100%	95.03%
> 1500 BTU	100%	97.13%	87.91%	100%	97.26%
> 3000 BTU	95%	98.96%	95%	98.96%	98.27%
> 6000 BTU	92.5%	99.74%	98.67%	98.45%	98.49%
> 7000 BTU	92.5%	100%	100%	98.46%	98.7%
> 10,000 BTU	87.5%	100%	100%	97.46%	97.84

low and should be increased to 1500 BTU (Kuijf et al., 2009). At this value, we maintained 100% sensitivity and a reduction of false positive patients (10 CIDP and one patient with POEMS, specificity 97.13%).

3.1. Optimal cut-off for sensitivity

Among the 80 anti-MAG neuropathy patients, four had BTU values below 3000 (at 1524, 1722, 2183, 2962 BTUs) and two were between 3000 and 6000 BTU (3170, 5206 BTUs). This meant that any value above 1500 BTU yielded a threshold value with < 100% sensitivity, with the sensitivity declining to 95% for cut-off of 3000 BTU and 92.5% for a cut-off of 6000 BTU (Table 1). The sensitivity remained the same for a cut-off level of 7000 BTU.

3.2. Optimal cut-off for specificity

At a cut-off of 1500 BTU, the specificity was at its lowest, at 97.13% (Table 1). With a positivity cut-off of 3000 BTU, we had 95% sensitivity and 98.96% specificity, since we had four false negative and four false positive patients (four CIDP). At the threshold of 6000 BTU, we had 92.5% sensitivity (six false negative patients) and 99.74% specificity with only one false positive (one CIDP patients with a BTU 6963). The specificity raised therefore to 100% using the 7000 BTU cut-off. Using the cut-off of 10,000 BTU, there were more false negative patients ($n = 10$) with a sensitivity of 87.5%.

Table 2 shows the value of sensitivity, specificity, PPV and NPV obtained analyzing anti-MAG patients vs CIDP patients as control sample. The values obtained have the same trend of previous analysis, with the best sensitivity at > 1500 BTU and better specificity and PPV at > 7000 BTU.

3.3. Relationship between BTU values and MAG titers form Western blot

Overall, there was a good correlation between the presence of increased titers of anti-MAG antibodies by ELISA and Western blot. However, comparing the level of these antibodies by ELISA and Western blot results, there was only a slight positive correlation ($r = 0.24$), indicating that there was only a moderate correspondence between these titers (Fig. 1). The correlation increased to $r = 0.30$,

Table 2

values of sensitivity, specificity, PPV, NPV, accuracy at different threshold of BTU (anti-MAG patients vs CIDP cohort as control sample). Similarly to previous analysis, the best value of Sensitivity was found at > 1500 BTU, the best value of Specificity and Accuracy at > 7000 BTU.

Threshold	Sensitivity	Specificity	PPV	NPV	Accuracy
> 1000 BTU	100%	90.99%	80%	100%	93.38%
> 1500 BTU	100%	95.5%	88.89%	100%	96.69%
> 3000 BTU	95%	98.2%	95%	98.2%	97.35%
> 6000 BTU	92.5%	99.55%	98.67%	97.36%	97.68%
> 7000 BTU	92.5%	100%	100%	97.37%	98.01%
> 10,000 BTU	87.5%	100%	100%	95.69%	96.69




Fig. 1. correlations between Western Blot (entire cohort, on the y-axis) and ELISA results (on x-axis). Analysis showed a low correlation ($r = 0.24$).




Fig. 2. correlations between Western Blot (patients with titers between 1:6400 and 1:25600) on y-axis and ELISA results (on x-axis). Analysis showed a low correlation ($r = 0.30$).

when we limited the analysis to patients with Western blot titers between 1:6400 and 1:25600 (inclusive, $n = 42$ patients), but was still not statistically significant (Fig. 2). The comparison of the level of anti-MAG antibodies in each patient with anti-MAG neuropathy is reported in the Supplementary table.

4. Discussion

Since the original report of anti-MAG IgM antibodies in a patient with chronic demyelinating neuropathy associated with serum IgM monoclonal gammopathy (Latov et al., 1980), several laboratories reported the presence of these antibodies in approximately 50% of patients with neuropathy and IgM monoclonal gammopathy (Nobile-Orazio, 2013). Different techniques were used to detect anti-MAG antibodies in these patients including ELISA or radioimmunoassay with purified MAG, Western blot after electrophoresis of brain or peripheral myelin proteins or of purified MAG, ELISA or overlay immunostaining after chromatography of the cross-reacting peripheral nerve glycolipids, indirect immunohistochemistry on peripheral nerve sections (Nobile-Orazio, 2013) and more recently immunofluorescence for reactivity to HNK-1 (Matà et al., 2011). This variability has led to some difference in the results of antibody detection (Nobile-Orazio et al., 1989; Pestronk et al., 1994; van den Berg et al., 1996; Weiss et al., 1999; Jaskowski

et al., 2004; Jaskowski et al., 2007; Matà et al., 2011) making it difficult a comparison of the results among the different laboratories. There was also some variability in the binding capabilities of IgM antibodies using these different antigens probably reflecting differences in the specificity (Nobile-Orazio et al., 1989; Pestronk et al., 1994; Fluri et al., 2003) or affinity (Ogino et al., 1994) of these antibodies. This might also explain the lack of correlation between anti-MAG titers and disease severity. In addition, most of these methods were time consuming and required the preparation of antigens or tissues from human autopsy.

In early 2000' a new commercial ELISA procedure using human purified MAG was introduced to determine serum anti-MAG antibody reactivity. This technique was shown to be sufficiently sensitive and specific (Kuijf et al., 2009) and shortly became a diffuse method for the measurement of these antibodies avoiding the local preparation of tissues or antigens from autopsy. It also has the advantage of facilitating the interpretation and comparison of the results among different Centers. However, there is not a clear consensus on the cut-off to be used for the best combination of sensitivity and specificity in the detection of these antibodies in patients with anti-MAG neuropathy. Previous studies reported that the commercially proposed cut-off titer have of > 1000 BTU titers also included some patients without have anti-MAG neuropathy (Caudie et al., 2006), so a new cut-off of 1500 BTU was proposed (Kuijf et al., 2009). An even higher cut-off of 10,000 BTU was recently proposed (Svahn et al., 2018), even if how this cut-off was determined was not specified. Considering the presence of some variability in the assessment measures, the Italian Neuroimmunological Society recently recommended that each Centre should calculate its own cut-off level for diagnostic confirmation (Franciotta et al., 2017).

We compared the results of anti-MAG antibodies using a commercial ELISA method and our currently used Western blot in our patients with anti-MAG neuropathy and with other neuropathies including CIDP, POEMS, patients with other neuropathies or with ALS and in healthy subjects. We did not use a control population of patients with IgM monoclonal gammopathy without neuropathy that we previously analyzed by Western blot (Nobile-Orazio et al., 2008) since we did not consider this population relevant in differential diagnosis with anti-MAG neuropathy.

With the recommended threshold value of 1000 BTU, we obtained 100% sensitivity for anti-MAG neuropathy, but also found 23 patients with other neuropathies including 20 with CIDP, two with POEMS and one with a sensory neuropathy of undefined etiology. Almost 10% of our tested CIDP patients therefore had values higher than the cut-off level. Using the cut-off value of 1500 BTU (Kuijf et al., 2009) we maintained a 100% sensitivity for anti-MAG neuropathy increasing the specificity from 94% to 97%. However, there were still 10 positive patients with CIDP (5%) and one with POEMS. A further increase of the cut-off level to 7000 BTU resulted in a 100% specificity with only six false negative patients (92.5% sensitivity). There was, therefore, a grey area between 1500 and 7000 BTU where a small number of patients with anti-MAG neuropathy resulting negative (6 patients) were balanced by an even larger number of positive patients with CIDP (10 patients). Using this cut-off measure a few patients would therefore need further investigation to exclude other possible diagnosis unless the clinical phenotypes is typical for anti-MAG neuropathy. Our proposed threshold of 7000 BTU permitted to clearly distinguish, in our series, patients with anti-MAG neuropathy from other neuropathies with only a moderate loss of sensitivity.

The implication of defining a clear-cut distinction in antibody titers between anti-MAG neuropathy and other neuropathy is important considering that POEMS syndrome is also associated with a monoclonal gammopathy and that the DADS phenotype of CIDP closely resembles anti-MAG neuropathy. All but one of our positive patients with CIDP had a typical CIDP and improved after therapy with intravenous immunoglobulins (IVIg) which is unusual for anti-MAG neuropathy (Lunn and Nobile-Orazio, 2016). Beside supporting the pathogenic distinction between anti-MAG neuropathy and CIDP within the boundaries of

chronic immune mediated neuropathies (Van den Bergh et al., 2020), this distinction may also allow to avoid the not so infrequent misdiagnosis of anti-MAG neuropathy in patients with CIDP and moderately increased antibodies. This has relevant therapeutic implication, since patients with CIDP often respond to steroids and IVIg that are usually ineffective in anti-MAG neuropathy (Lunn and Nobile-Orazio, 2016). It might be also important to define the high level of anti-MAG neuropathy that might exclude the diagnosis of CIDP in the current EFNS/PNS guidelines for this diagnosis (van den Bergh et al., 2010).

Similarly to what reported in other studies, comparing the sensitivity of different methods for the detection of anti-MAG antibodies (Nobile-Orazio et al., 1989; Jaskowski et al., 2004; Jaskowski et al., 2007; Kuijf et al., 2009), there was not a strict correlation between anti-MAG levels by Western blot and ELISA. This applied to the entire cohort of patients (r-value 0.24) and to patients with Western blot titers between 1:6400 and 1:25600 (r-value 0.29). As already mentioned, this may reflect difference in the specificity or affinity of these antibodies for MAG (Nobile-Orazio et al., 1989; Pestronk et al., 1994; Van den Berg et al., 1996; Weiss et al., 1999; Matà et al., 2011) or in their access to the antigen using different substrate for the analysis. The use of a fixed serum dilution of 1:1000 in the ELISA techniques may also allow the binding of lower affinity antibodies that might disappear with higher serum dilution.

In conclusion, we suggest that more stringent criteria for the definition of positivity and some caution in the interpretation of moderately increased anti-MAG antibody levels should be used for this otherwise accurate and easy to use procedure.

Author contribution

ENO, GL, CG and BPS conceived, organized and designed the study, reviewed and commented on the statistical analysis, wrote the first draft of the report and reviewed the report. EM performed statistical analysis. FG, FT, PED, FM, DC, MF, GA, GC, GAM, AMC, GL, TR, GC contributed to the conception, organization, and execution of the research project, reviewed and commented on the statistical analysis and the report.

Ethical approval

The study was conducted according to the declaration of Helsinki and was approved by the local ethics committee. All the patients gave written informed consent.

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Funding

This study was supported by a Grant from Regione Lombardia, Italy, for patients from this Region and subsequently extended to other Italian Centers and by the Italian Ministry of Health "Ricerca Finalizzata 2016 (Grant code: RF-2016-02361887) to Humanitas Clinical and Research Center, IRCCS. The study was also supported by unrestricted grants from Kedrion Biopharma (Italy), CSL Behring (Italy), Humanitas Clinical and Research Institute (Milan, Italy), and GBS-CIDP Foundation International (USA). The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; decision to submit the manuscript for publication.

Declaration of Competing Interest

E.N.O. reported personal fees for Advisory or Scientific Board from Kedrion, Italy, Baxter, Italy, Novartis, Switzerland, CSL-Behring, Italy, LFB, France, Astellas, the Netherlands, outside the submitted work and travel grants to attend Scientific Meeting from Baxter, Grifols, Kedrion, and Novartis, Italy. P.E.D. reported travel grants to attend scientific meetings from CSL Behring and Kedrion. G.L. reported travel grants to attend scientific meetings from CSL Behring and Kedrion. D.C. reported honoraria for lecturing from Shire, CSL Behring, and Kedrion and travel grants to attend scientific meeting from Shire, Kedrion, and CSL Behring. G.C. reported travel grants to attend scientific meetings from CSL Behring and Kedrion. F.M. reported personal fees for scientific events from CSL Behring and has received travel grants to attend scientific meetings from CSL Behring and Kedrion. G.C. reported honoraria for lecturing and travel grants to attend scientific meetings from Kedrion. M.F. has served on scientific advisory boards for CSL Behring and Sarepta Therapeutics and has received travel grants from Sanofi Genzyme, Kedrion, Baxter and CSL Behring to attend scientific meeting. G.A.M. reported consultancy fees and travel fundings from CSL Behring, Kedrion, Shire and Grifols. G.A. reported honoraria for lecturing from Kedrion and Sanofi-genzyme, travel grants from Kedrion, Sanofi-Genzyme and LJ Pharma. The other authors declare no conflict of interest.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jneuroim.2020.577288>.

References

- Brooks, B.R., Miller, R.G., Swash Munsat, T.L., World Federation of Neurology Research Group on Motor Neuron Diseases, 2000. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Other Motor. Neuron. Disord* 1, 293–299.
- Caudie, C., Kaygisiz, F., Jaquet, P., Petiot, P., Gonnard, P.M., Antoine, J.C., Vial, C., 2006. Diagnostic value of autoantibodies to MAG by ELISA Buhlmann in 117 immune-mediated peripheral neuropathies associated with monoclonal IgM to SGPG/SGLPG. *Ann Biol Clin (Paris)* 64 (4), 353–359.
- Chaudhry, H.M., Mauermann, M.L., Rajkumar, S.V., 2017. Monoclonal gammopathy-associated peripheral neuropathy: diagnosis and management. *Mayo Clin. Proc.* 92 (5), 838–850.
- Dalakas, M.C., 2018. Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies. *Ther. Adv. Neurol. Disord.* 11 (Jan 15) 1756285617746640.
- Dispenzieri, A., Kourelis, T., Buadi, F., 2018. POEMS syndrome: diagnosis and investigative work-up. *Hematol. Oncol. Clin. North Am.* 32 (1), 119–139.
- Fluri, F., Ferracin, F., Erne, B., Steck, A.J., 2003. Microheterogeneity of anti-myelin-associated glycoprotein antibodies. *J. Neurol. Sci.* 207, 43–49.
- Franciotta, D., Gastaldi, M., Benedetti, L., Garnerio, M., Biagioli, T., Brogi, M., Costa, G., Fadda, E., Andretta, F., Simoncini, O., Giannotta, C., Bazzigaluppi, E., Fazio, R., Bedin, R., Ferraro, D., Mariotto, S., Ferrari, S., Galloni, E., De Riva, V., Zardini, E., Cortese, A., Nobile-Orazio, E., 2017. Diagnostics of anti-MAG antibody polyneuropathy. *Neurol. Sci.* 38 (Suppl. 2), 249–252.
- Gosselin, S., Kyle, R.A., Dyck, P.J., 1991. Neuropathy associated with monoclonal gammopathies of undetermined significance. *Ann. Neurol.* 30 (1), 54–61.
- Hadden, R.D.M., Nobile-Orazio, E., Sommer, C., Hahn, A., Illa, I., Morra, E., Pollard, J., Hughes, R.A.C., Bouche, P., Cornblath, D., Evers, E., Koski, C.L., Léger, J.M., Van den Bergh, P., van Doorn, P., van Schaik, I.N., 2006. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. *Eur. J. Neurol.* 13, 809–818.
- Jaskowski, T.D., Martins, T.B., Litwin, C.M., Hill, H.R., 2004. Immunoglobulin (Ig) M Antibody against Myelin Associated Glycoprotein (MAG): a comparison of methods. *J. Clin. Lab. Anal.* 18, 247–250.
- Jaskowski, T.D., Prince, H.E., Greer, R.W., Litwin, C.M., Hill, H.R., 2007. Further comparisons of assays for detecting MAG IgM autoantibodies. *J. Neuroimmunol.* 187, 175–178.
- Kuijf, M.L., Eurelings, M., Tio-Gillen, A.P., van Doorn, P.A., van den Berg, L.H., Hooijkaas, H., Stork, J., Notermans, N.C., Jacobs, B.C., 2009. Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy. *Neurology* 73 (9), 688–695.
- Latov, N., Sherman, W.H., Nemni, R., Galassi, G., Shyong, J.S., Penn, A.S., Chess, L., Olatre, M.R.L., Rowland, P., Osserman, E.F., 1980. Plasma-cell dyscrasia and

- peripheral neuropathy with a monoclonal antibody to peripheral-nerve myelin. *N. Engl. J. Med.* 303 (11), 618–621.
- Lunn, M.P., Nobile-Orazio, E., 2016. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. *Cochrane Database Syst. Rev.* 10, CD002827.
- Matà, S., Ambrosini, S., Mello, T., Lolli, F., Minciocchi, D., 2011. Antimyelin associated glycoprotein antibodies recognize HNK-1 epitope on CNS. *J. Neuroimmunol.* 236, 99–105.
- Nobile-Orazio, E., 2013. Neuropathy and monoclonal gammopathy. *Handbook of Clinical Neurology*. Vol. 115 (3rd series); peripheral nerve disorders. G. Said and C. Krarup, editors. Elsevier BV, Amsterdam, the Netherlands. 115. pp. 443–459.
- Nobile-Orazio, E., Vietorisz, T., Messito, M.J., Sherman, W.H., Latov, N., 1983. Anti-MAG IgM antibodies in patients with neuropathy and IgM M proteins: detection by ELISA. *Neurology* 33 (7), 939–942.
- Nobile-Orazio, E., Francomano, E., Daverio, R., Barbieri, S., Marmioli, P., Manfredini, E., Carpo, M., Moggio, M., Legname, G., Baldini, L., Scarlato, G., 1989. Anti-myelin-associated glycoprotein IgM antibody titers in neuropathy associated with macroglobulinemia. *Ann. Neurol.* 26, 543–550.
- Nobile-Orazio, E., Manfredini, E., Carpo, M., Meucci, N., Monaco, S., Ferrari, S., Bonetti, B., Cavaletti, G., Gemignani, F., Durelli, L., 1994. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. *Ann. Neurol.* 36 (3), 416–424.
- Nobile-Orazio, E., Gallia, F., Terenghi, F., Allaria, S., Giannotta, C., Carpo, M., 2008. How useful are anti-neural IgM antibodies in the diagnosis of chronic immune-mediated neuropathies? *J. Neurol. Sci.* 266, 156–163.
- Ogino, M., Tatum, A.H., Latov, N., 1994. Affinity studies of human anti-MAG antibodies in neuropathy. *J. Neuroimmunol.* 52, 41–46.
- Pestronk, A., Li, F., Bieser, K., Choksi, R., Whitton, A., Kornberg, A.J., Goldstein, J.M., Yee, W.-C., 1994. Anti-MAG antibodies: major effects of antigen purity and antibody cross-reactivity on ELISA results and clinical correlation. *Ann. Neurol.* 44, 1131–1137.
- Svahn, J., Petiot, P., Antoine, J.C., Vial, C., Delmont, E., Viala, K., Steck, A.J., Magot, A., Cauquil, C., Zarea, A., Echaniz-Laguna, A., Iancu Ferfoggia, R., Gueguen, A., Magy, L., Leger, J.M., Kuntzer, T., Ferraud, K., Lacour, A., Camdessanche, J.P., Francophone anti-MAG cohort Group, 2018. Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features. *J. Neurol. Neurosurg. Psychiatry* 89 (5), 499–505.
- Van den Berg, L., Hays, A.P., Nobile-Orazio, E., Kinsella, L.J., Manfredini, E., Corbo, M., Rosoklijam, G., Younger, D.S., Lovelace, R.E., Trojaburg, W., Lange, D.E., Goldstein, S., Delfiner, J.S., Sadiq, S., Sherman, W.H., Latov, N., 1996. Anti-MAG and anti-SGPG antibodies in neuropathy. *Muscle Nerve* 19, 637–643.
- Van den Bergh, P.Y., Hadden, R.D., Bouche, P., Cornblath, D.R., Hahn, A., Illa, I., Koski, C.L., Leger, J.M., Nobile-Orazio, E., Pollard, J., Sommer, C., van Doorn, P.A., van Schaik, I.N., European Federation of Neurological Societies/Peripheral Nerve Society, 2010. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society—First Revision. *Eur. J. Neurol.* 17, 356–363
Corrigendum in: *Eur J Neurol* 2011;18:276.
- Van den Bergh, P.Y.K., van Doorn, P.A., Jacobs, B.C., Querol, L., Bunschoten, C., Cornblath, D.R., 2020. Boundaries of chronic inflammatory demyelinating polyradiculoneuropathy. *J. Peripher. Nerv. Syst.* 25, 4–8.
- Weiss, M.D., Dalakas, M.C., Lauter, C.J., Willison, H.J., Quarles, R.H., 1999. Variability in the Binding of anti-MAG and anti-SGPG Antibodies to Target Antigens in Demyelinating Neuropathy and IgM Paraproteinemia. *J. Neuroimmunol Mar.* 1-2 (1-2), 174–184. [https://doi.org/10.1016/s0165-5728\(98\)00247-1](https://doi.org/10.1016/s0165-5728(98)00247-1).